Senescence, which affects stem cells, essential for therapeutic usage, occurs in our bodies as we age. But when they reach the senescent stage, they cease making vital biomolecules. Researchers should stop older cells from entering the culture to stop senescence. Biomolecules needed for treatments are produced by mesenchymal stem cells derived from fat tissue. Researchers should modify the environment to regulate the oxidative state and employ antioxidants to rescue stem cells from senescence and maintain healthy behavior to avoid senescence. While antioxidant therapy for cells can postpone senescence, there are several drawbacks to existing antioxidant delivery techniques, including significant differences in the quantity of medication released over time and between cells. Researchers have developed a novel, dependable, long-lasting, and variable microfluidics technology for delivering antioxidants to stem cells.
Antioxidants are used in the novel technology as crystals stabilized by polymers. By employing microfluidics technology that enables scientists to operate with exceedingly small volumes of fluid, the researchers can produce crystals of the same size and dose, limiting variance in drug release between cells.
Traditional methods develop crystals within reactors. Using microfluidics technology, they may create tiny, comparable-sized individual crystals, which decreases variance in drug release rate since each drop serves as a little reactor. The medicine is released uniformly throughout time thanks to the crystals’ slower dissolution rate than conventional techniques, which also lengthens the effective period of the drug.
Related Content: Chip-Based Biosensor For Optofluidic Sensing Devices